Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

OBJECTIVES: The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis (UC) has been reported up to week 52 from the placebo-controlled trials ULTRA (Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab) 1 and 2. Up to 4 years of data f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Gastroenterol
Hlavní autoři: Colombel, Jean-Frederic, Sandborn, William J, Ghosh, Subrata, Wolf, Douglas C, Panaccione, Remo, Feagan, Brian, Reinisch, Walter, Robinson, Anne M, Lazar, Andreas, Kron, Martina, Huang, Bidan, Skup, Martha, Thakkar, Roopal B
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Inflammatory Bowel Disease
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4223868/
https://ncbi.nlm.nih.gov/pubmed/25155227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2014.242
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky